Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00099619
First received: December 17, 2004
Last updated: September 18, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2005
  Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
No publications provided by Bristol-Myers Squibb

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):